A- A A+

Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review.

Babiker A, Hassan M, Muhammed S, Taylor G, Poonia B, Shah A, Bagchi S.

Clin Cardiol. 2019 Nov 30. doi: 10.1002/clc.23299.

https://onlinelibrary.wiley.com/doi/full/10.1002/clc.23299

HepCare Europe: a new user-friendly hepatitis C care service model. What have we learned? What are the remaining challenges?

Rockstroh JK, Yazdanpanah Y.

J Antimicrob Chemother. 2019 Nov 1;74(Supplement_5):v2-v4. doi: 10.1093/jac/dkz447. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883388/

Hepatitis C Virus Treatment Status and Barriers among Patients in Methadone Maintenance Treatment Clinics in Guangdong Province, China: A Cross-Sectional, Observational Study.

Liu Y, Zou X, Chen W, Gong C, Ling L.

Int J Environ Res Public Health. 2019 Nov 12;16(22). pii: E4436. doi: 10.3390/ijerph16224436.

https://www.mdpi.com/1660-4601/16/22/4436

Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).

Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg EM, Johansson KA; INTRO-HCV Study Group.

BMC Infect Dis. 2019 Nov 8;19(1):943. doi: 10.1186/s12879-019-4598-7.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839172/

Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?

Zuckerman AD, Douglas A, Whelchel K, Choi L, DeClercq J, Chastain CA.

PLoS One. 2019 Nov 21;14(11):e0225434. doi: 10.1371/journal.pone.0225434.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0225434

Direct-acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV-infected patients.

Ing Lorenzini K, Girardin F.

Liver Int. 2019 Oct 26. doi: 10.1111/liv.14283. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31654604

The Impact of Hepatitis C Virus Infection on Buprenorphine Dose in Pregnancy.

McDowell ML, Tonismae TR, Slaven JE, Abernathy MP, Shanks AL, Benjamin TD, Quinney SK.

Am J Perinatol. 2019 Oct 26. doi: 10.1055/s-0039-1698838.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31655490

National Trends in Hepatitis C Infection by Opioid Use Disorder Status Among Pregnant Women at Delivery Hospitalization - United States, 2000-2015.

Ko JY, Haight SC, Schillie SF, Bohm MK, Dietz PM.

MMWR Morb Mortal Wkly Rep. 2019 Oct 4;68(39):833-838. doi: 10.15585/mmwr.mm6839a1.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776372/

Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.

Shili-Masmoudi S, Sogni P, de Ledinghen V, Esterle L, Valantin M-A, Poizot-Martin I, et al. (2019) 

PLoS ONE 14(1): e0211286. doi.org/10.1371/journal.pone.0211286

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211286

Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data.

Yen Y-H, Chen C-H, Hung C-H, Wang J-H, Lu S-N, Kee K-M, et al. (2019) 

PLoS ONE 14(10): e0222605. doi.org/10.1371/journal.pone.0222605

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0222605

Access to unauthorized hepatitis C generics: Perception and knowledge of physicians, pharmacists, patients and non-healthcare professionals.

Garcia A, Moore Boffi S, Gayet-Ageron A, Vernaz N (2019) 

PLoS ONE 14(10): e0223649. doi.org/10.1371/journal.pone.0223649

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0223649

Chronic HCV infection and neuropsychiatric dysfunction.

Fortini I, Arouca EMG, Tengam FM, Nitrini R.

eNeurologicalSci. 2019 Sep 5;17:100206. doi: 10.1016/j.ensci.2019.100206. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806448/

Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS‐FANTASIO study),

Barre, T., Marcellin, F., Di Beo, V., Delorme, J., Rojas Rojas, T., Mathurin, P., Protopopescu, C., Bailly, F., Coste, M., Authier, N., Carrieri, M. P., and Rolland, B. ( 2019) 

Addiction. doi.org/10.1111/add.14820. 

https://onlinelibrary.wiley.com/doi/full/10.1111/add.14820

Rapid point-of-care HCV RNA quantification in capillary whole blood for diagnosing chronic HCV infection, monitoring treatment and detecting reinfection.

Bregenzer A, Warmann N, Ottiger C, Fux CA.

Swiss Med Wkly. 2019 Oct 27;149:w20137. doi: 10.4414/smw.2019.20137.

https://smw.ch/article/doi/smw.2019.20137

Hepatitis C Virus Prevalence and Incidence in a Large Nationwide Sample of Patients in Opioid Substitution Treatment in Germany: A Prospective Cohort Study.

Schulte B, Schmidt CS, Strada L, Rosenkranz M, Schäfer I, Verthein U, Reimer J.

Clin Infect Dis. 2019 Oct 21. pii: ciz661. doi: 10.1093/cid/ciz661. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31631215

Launch of Injecting Drug User Implementation Tool Training Manual 

INPUD is very excited to launch the Injecting Drug User Implementation Tool Training Manual and accompanying slides.

Developed jointly by UNODC and INPUD, in collaboration with other partners, the guidance document Implementing Comprehensive HIV Programmes with People who Inject Drugs: Practical Approaches from Collaborative Interventions – otherwise known as the Injecting Drug User Implementation Tool (IDUIT) – was published in 2016.  It describes how to implement effective programmes and services for HIV and HCV prevention interventions for and with people who inject drugs.

The training manual is designed to support the roll-out of the IDUIT through capacity building at regional, country or local level. It has been developed to facilitate the work of trainers in organising and delivering training and workshops on the IDUIT to communities of people who use drugs to help them serve their own community in line with the evidence based and human rights-based approaches outlined in the IDUIT, and to interact with a wide range of governmental and non-governmental organisations, including public health and drug policy makers, and harm reduction and HIV programme managers and staff. (INPUD - International Network of People who Use Drugs, Oktober 2019)

https://www.inpud.net/en/launch-injecting-drug-user-implementation-tool-training-manual

HCV, injection drug use, and the importance of harm reduction in Kenya

Zaller, Nickolas et al.

The Lancet Infectious Diseases, Volume 19, Issue 11, 1158 - 1159 

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30407-4/fulltext

USA. Pharma Sells States On ‘Netflix Model’ To Wipe Out Hep C. But At What Price?

When a long, black bus bearing the logo of drugmaker AbbVie rolls through Washington state next year, it will promote a new effort to eradicate hepatitis C infections.

The state is paying for the marketing campaign as part of a deal to give AbbVie the exclusive right to treat its citizens who have the potentially deadly liver disease. Armed with its medication, Mavyret, AbbVie beat out rivals Merck and Gilead Sciences in a blind bidding process.

It’s the second time this year that a state has struck a novel deal with a pharmaceutical company to obtain drugs that can cure hepatitis C ― with discounts from a price that came to market at $84,000 for a course of treatment.

The drugmakers are in a race to treat the 2.4 million people in the U.S, with the viral infection.  (KHN – Kaiser Health News, USA, 25.10.2019)

https://khn.org/news/pharma-sells-states-on-netflix-model-to-wipe-out-hep-c-but-at-what-price/

Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study).

Barre T, Marcellin F, Di Beo V, Delorme J, Rojas Rojas T, Mathurin P, Protopopescu C, Bailly F, Coste M, Authier N, Carrieri MP, Rolland B.

Addiction. 2019 Oct 8. doi: 10.1111/add.14820. 

Abstract

https://onlinelibrary.wiley.com/doi/abs/10.1111/add.14820

Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West.

Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, Le A, Liu M, Maeda M, Nguyen B, Ramrakhiani N, Henry L, Cheung R, Tamori A, Kumada T, Tanaka Y, Yu ML, Toyoda H, Nguyen MH.

Hepatology. 2019 Oct 14. doi: 10.1002/hep.30988.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31610027

Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes.

Vrancken B, Cuypers L, Pérez AB, Chueca N, Anton-Basantas J, de la Iglesia A, Fuentes J, Pineda JA, Téllez F, Bernal E, Rincón P, Von Wichman MA, Fuentes A, Vera F, Rivero-Juárez A, Jiménez M, Vandamme AM, García F.

J Hepatol. 2019 Oct 1. pii: S0168-8278(19)30476-3. doi: 10.1016/j.jhep.2019.08.010.

https://www.ncbi.nlm.nih.gov/pubmed/31585736

USA. COMPA Members Use Telemedicine in Clinical Trial to Assess Hepatitis C Management in Methadone-Maintained Patients

Twelve opioid treatment programs (OTPs) in New York State are participating in a $7 million clinical trial integrating treatment of hepatitis C virus (HCV) infection in patients taking methadone. The clinical trial, “Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals,” being carried out at the University at Buffalo (UB), is aimed at showing how telemedicine can be useful in treating these and other patients. The Patient-Centers Outcomes Research Institute (PCORI) provided the funding and the telecommunications technology to the university. (ATForum, USA, 11.10.2019)

http://atforum.com/2019/10/compa-members-use-telemedicine-in-clinical-trial-to-assess-hepatitis-c-management-in-methadone-maintained-patients/

Levamisole-induced Vasculitis in a Hepatitis C Patient: A General Medicine Ward Perspective on Diagnosis and Management.

Latif Z, Pour-Ghaz I, Bergeron JB.

Cureus. 2019 Jul 22;11(7):e5198. doi: 10.7759/cureus.5198.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758961/

Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).

Hickman M, Dillon JF, Elliott L, De Angelis D, Vickerman P, Foster G, Donnan P, Eriksen A, Flowers P, Goldberg D, Hollingworth W, Ijaz S, Liddell D, Mandal S, Martin N, Beer LJZ, Drysdale K, Fraser H, Glass R, Graham L, Gunson RN, Hamilton E, Harris H, Harris M, Harris R, Heinsbroek E, Hope V, Horwood J, Inglis SK, Innes H, Lane A, Meadows J, McAuley A, Metcalfe C, Migchelsen S, Murray A, Myring G, Palmateer NE, Presanis A, Radley A, Ramsay M, Samartsidis P, Simmons R, Sinka K, Vojt G, Ward Z, Whiteley D, Yeung A, Hutchinson SJ.

BMJ Open. 2019 Sep 24;9(9):e029538. doi: 10.1136/bmjopen-2019-029538.

https://bmjopen.bmj.com/content/9/9/e029538.long

Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV).

Pisaturo M, Macera M, Alessio L, Calò F, Coppola N.

Viruses. 2019 Sep 13;11(9). pii: E850. doi: 10.3390/v11090850. Review.

https://www.mdpi.com/1999-4915/11/9/850

The case for a universal hepatitis C vaccine to achieve hepatitis C elimination.

Scott N, Wilson DP, Thompson AJ, Barnes E, El-Sayed M, Benzaken AS, Drummer HE, Hellard ME.

BMC Med. 2019 Sep 18;17(1):175. doi: 10.1186/s12916-019-1411-9.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749704/

Definition of the profiles of hepatitis C virus patients based on the identification of risky practices in Spain.

Calleja Panero JL, Lens García S, Fernández Bermejo M, Crespo García J.

Rev Esp Enferm Dig. 2019 Sep 17;111. doi: 10.17235/reed.2019.6169/2019. 

https://www.reed.es/definition-of-the-profiles-of-hepatitis-c-virus-patients-based-on-the-identification-of-risky-practices-in-spain3954

DOES IT WORK? -a randomized controlled trial to test the efficacy of HCV and HIV-related education on drug users in MMT, China.

Zhang JY, Li ZB, Zhang L, Wang J, Huang LP, Zhan GL, Li Z, Du J, Zhao M.

BMC Infect Dis. 2019 Sep 5;19(1):774. doi: 10.1186/s12879-019-4421-5.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727322/

HBsAg, Anti-HCV and Anti-HIV Seroprevalance Among Drug Users: a Retrospective Assessment.

Altuğlu I, Tanyeri S, Zeytinoğlu A, Altintoprak AE.

Noro Psikiyatr Ars. 2019 Jul 16;56(3):186-190. doi: 10.29399/npa.23505.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732810/

Hepatitis C virus modelled as an indirectly transmitted infection highlights the centrality of injection drug equipment in disease dynamics.

Miller-Dickson MD, Meszaros VA, Almagro-Moreno S, Brandon Ogbunugafor C.

J R Soc Interface. 2019 Sep 27;16(158):20190334. doi: 10.1098/rsif.2019.0334. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769301/